BACKGROUND: Detectable HIV-1 RNA at delivery is the strongest predictor of mother-to-child transmission. The risk factors for detectable HIV, including type of regimen, are unknown. We evaluated factors, including highly active antiretroviral (HAART) regimen, associated with detectable HIV-1 RNA at delivery in the Women and Infants Transmission Study (WITS). METHODS: Data from 630 HIV-1-infected women who enrolled from 1998 to 2005 and received HAART during pregnancy were analyzed. Multivariable analyses examined associations between regimens, demographic factors, and detectable HIV-1 RNA (>400 copies/milliliter) at delivery. RESULTS: Overall, 32% of the women in the cohort had detectable HIV-1 RNA at delivery. Among the subset of 364 HAART-experienced women, a lower CD4 cell count at enrollment [adjusted odds ratio (AOR) = 1.20 per 100 cells/microL, confidence interval (CI) 1.04 to 1.37] and higher HIV-1 RNA at enrollment (AOR = 1.52 per log10 copies/milliliter, CI 1.32 to 1.75) were significantly associated with detectable HIV-1 RNA levels at delivery. For the 266 HAART-naive women, both lower CD4 cell count at enrollment (AOR = 1.24 per 100 cells/microL, CI 1.05 to 1.48) and higher HIV-1 RNA at enrollment (AOR = 1.35 per log10 copies/milliliter, CI 1.12 to 1.63) were associated with detectable HIV-1 RNA at delivery. In addition, age at delivery (AOR = 0.92 per 10 years older, CI 0.86 to 0.99) and maternal illicit drug use (AOR = 3.15, CI 1.34 to 7.41) were significantly associated with detectable HIV-1 RNA at delivery among HAART-naive women. Type of HAART regimen was not significant in either group. CONCLUSIONS: Lack of viral suppression at delivery was common in the WITS cohort, but differences by antiretroviral regimen were not identified. Despite a transmission rate below 1% in the last 5 years of the WITS cohort, improved measures to maximize HIV-1 RNA suppression at term among high-risk women are warranted.
BACKGROUND: Detectable HIV-1 RNA at delivery is the strongest predictor of mother-to-child transmission. The risk factors for detectable HIV, including type of regimen, are unknown. We evaluated factors, including highly active antiretroviral (HAART) regimen, associated with detectable HIV-1 RNA at delivery in the Women and Infants Transmission Study (WITS). METHODS: Data from 630 HIV-1-infectedwomen who enrolled from 1998 to 2005 and received HAART during pregnancy were analyzed. Multivariable analyses examined associations between regimens, demographic factors, and detectable HIV-1 RNA (>400 copies/milliliter) at delivery. RESULTS: Overall, 32% of the women in the cohort had detectable HIV-1 RNA at delivery. Among the subset of 364 HAART-experienced women, a lower CD4 cell count at enrollment [adjusted odds ratio (AOR) = 1.20 per 100 cells/microL, confidence interval (CI) 1.04 to 1.37] and higher HIV-1 RNA at enrollment (AOR = 1.52 per log10 copies/milliliter, CI 1.32 to 1.75) were significantly associated with detectable HIV-1 RNA levels at delivery. For the 266 HAART-naive women, both lower CD4 cell count at enrollment (AOR = 1.24 per 100 cells/microL, CI 1.05 to 1.48) and higher HIV-1 RNA at enrollment (AOR = 1.35 per log10 copies/milliliter, CI 1.12 to 1.63) were associated with detectable HIV-1 RNA at delivery. In addition, age at delivery (AOR = 0.92 per 10 years older, CI 0.86 to 0.99) and maternal illicit drug use (AOR = 3.15, CI 1.34 to 7.41) were significantly associated with detectable HIV-1 RNA at delivery among HAART-naive women. Type of HAART regimen was not significant in either group. CONCLUSIONS: Lack of viral suppression at delivery was common in the WITS cohort, but differences by antiretroviral regimen were not identified. Despite a transmission rate below 1% in the last 5 years of the WITS cohort, improved measures to maximize HIV-1 RNA suppression at term among high-risk women are warranted.
Authors: Kathryn Anastos; Michael F Schneider; Stephen J Gange; Howard Minkoff; Ruth M Greenblatt; Joseph Feldman; Alexandra Levine; Robert Delapenha; Mardge Cohen Journal: J Acquir Immune Defic Syndr Date: 2005-08-15 Impact factor: 3.731
Authors: L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo Journal: N Engl J Med Date: 1999-08-05 Impact factor: 91.245
Authors: P M Garcia; L A Kalish; J Pitt; H Minkoff; T C Quinn; S K Burchett; J Kornegay; B Jackson; J Moye; C Hanson; C Zorrilla; J F Lew Journal: N Engl J Med Date: 1999-08-05 Impact factor: 91.245
Authors: Laurence S Magder; Lynne Mofenson; Mary E Paul; Carmen D Zorrilla; William A Blattner; Ruth E Tuomala; Phil LaRussa; Sheldon Landesman; Kenneth C Rich Journal: J Acquir Immune Defic Syndr Date: 2005-01-01 Impact factor: 3.731
Authors: Sharon Walmsley; Barry Bernstein; Martin King; José Arribas; Gildon Beall; Peter Ruane; Margaret Johnson; David Johnson; Richard Lalonde; Anthony Japour; Scott Brun; Eugene Sun Journal: N Engl J Med Date: 2002-06-27 Impact factor: 91.245
Authors: Katherine Tassiopoulos; Jennifer S Read; Susan Brogly; Kenneth Rich; Barry Lester; Stephen A Spector; Ram Yogev; George R Seage Journal: AIDS Behav Date: 2010-12
Authors: Kathryn Rough; Katherine Tassiopoulos; Deborah Kacanek; Raymond Griner; Ram Yogev; Kenneth C Rich; George R Seage Journal: AIDS Date: 2015-01-02 Impact factor: 4.177
Authors: Ingrid T Katz; Erin Leister; Deborah Kacanek; Michael D Hughes; Arlene Bardeguez; Elizabeth Livingston; Alice Stek; David E Shapiro; Ruth Tuomala Journal: Ann Intern Med Date: 2015-01-20 Impact factor: 25.391
Authors: Paige L Williams; Rohan Hazra; Russell B Van Dyke; Cenk Yildirim; Marilyn J Crain; George R Seage; Lucy Civitello; Angela Ellis; Laurie Butler; Kenneth Rich Journal: AIDS Date: 2016-01-02 Impact factor: 4.177
Authors: Ilaria Izzo; Maria A Forleo; Salvatore Casari; Eugenia Quiros-Roldan; Michele Magoni; Giampiero Carosi; Carlo Torti Journal: BMC Public Health Date: 2011-02-21 Impact factor: 3.295
Authors: Florence M Momplaisir; Kathleen A Brady; Thomas Fekete; Dana R Thompson; Ana Diez Roux; Baligh R Yehia Journal: PLoS One Date: 2015-07-01 Impact factor: 3.240